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Objective. Determine which factors predict multiple pregnancy in gonadotropin-intrauterine insemination cycles so that
cancellation criteria might be developed. Study Design. Retrospective chart review of all patients undergoing gonadotropin-
intrauterine insemination over a continuous 36 month period. Results. No factors examined were able to predict the occurrence of
multiple pregnancy. Conclusion. Multiple pregnancy is an unavoidable complication of gonadotropin-intrauterine insemination
treatment.
1.Introduction
Artiﬁcial insemination is an eﬀective treatment for subfer-
tility, originally described in 1957 by Mastroianni [1]. In-
seminations are commonly accompanied by ovulation stim-
ulation, which increase the pregnancy but markedly elevate
the risk of multiple birth. In a multicenter randomized trial,
Guzick and colleagues [2] reported pregnancy rates per in-
semination cycle of 2% with intracervical insemination
(ICI), 5% with intrauterine insemination (IUI), 4% with
gonadotropin-ICI, and 9% with gonadotropin-IUI. Thus,
even gonadotropin with ICI was less eﬃcacious than IUI
alone.
In 2004 [3], the Centers for Disease Control reported
that the twin birth rate was 3% at 32.3 per 1000 total live
births, a high record. This is a 71% increase since 1980
when the rate was 18.9 per 1000 total live births. In a study
of higher-order multiples in 1997 [4], it was found that
43% were from assisted reproductive technology, 38% were
from ovulation inducing drugs, and 20% were spontaneous.
Concerns about obstetrical and neonatal risks associated
with multiple pregnancy suggest the need to develop better
predictors of multiple gestation.
Improvements in IVF have led to increasing pregnancy
rates at the same time that the number of embryos trans-
ferred has declined. The American Society for Reproductive
Medicine has issued practice guidelines [5] on the number of
embryos suggested for transfer in IVF. Together, these forces
have led to a drastic reduction in high-order multiple births
after IVF. In the most recent SART report [6] (2009 National
SummaryData,http://www.sart.org/),lessthan2%ofallIVF
births involve 3 or more babies. The same practices cannot
be used to limit multiple birth after gonadotropin-IUI treat-
ments [7]. Despite its greater associated risks, gonadotropin-
IUI has remained a popular treatment option since it is more
aﬀordable than IVF for many couples.
Physicians have long sought ways to predict pregnancy
and multiple gestations during gonadotropin-IUI. Obvious
factors are number of follicles and peak estradiol. Peak
estradiol should be a true reﬂection of the entire developing
follicular cohort, both large- and intermediate-sized follicles.
Some authors [8, 9] have found a correlation between peak
estradiol and the number of follicles while others have not
[11]. Adding to the confusion are signiﬁcant diﬀerences
between studies in terms of which follicle sizes they have
considered “large” and whether they have used mean or2 ISRN Obstetrics and Gynecology
largest diameter. In addition, there are variations in follicle
sizemeasurementsbothwithinandbetweenobservers,along
with variations in image quality and resolution between ul-
trasound machines.
Using our gonadotropin-IUI database, we sought to de-
terminewhichpatient-speciﬁcandcycle-speciﬁcfactorswere
predictive of high-order (three or more sacs) multiple and
any (two or more sacs) multiple pregnancy.
2.MaterialsandMethods
IRBapprovedretrospectivechartreviewofallgonadotropin-
IUI cycles at the New Jersey Medical School Center for
Reproductive Medicine from January 1, 1998, through De-
cember 31, 2000. 861 gonadotropin-IUI cycles were per-
formed on 428 patients. No cycles were excluded from
analysis. Our hypothesis was that number of mature follicles
and/or peak estradiol level would be most predictive of
multiple pregnancy after gonadotropin-IUI therapy.
A baseline transvaginal ultrasound was performed on
cycledays1,2,or3toexcluderesidualcystspriortoinitiating
treatment. Ovulation induction using gonadotropins began
on day 3 of a spontaneous menstrual cycle or a progestin-
induced withdrawal bleed. Starting dose of gonadotropins
was determined by the physician. During this period, both
recombinant and urinary gonadotropins were used depend-
ing on physician preference and product availability. Trans-
vaginal ultrasound was performed and estradiol level drawn
after three to ﬁve nights of medication. Ultrasounds and es-
tradiol levels were repeated as clinically indicated. Medica-
tionswereadjustedasneeded.Folliclesizewasdeterminedby
transvaginal ultrasound taking two measurements perpen-
dicular to each other and recording the average in millime-
ters. When one or more follicles reached a mean diameter
of ≥16mm, hCG 5,000IU was given intramuscularly. Single
IUI was performed 38 hours after hCG. hCG 2,500IU was
administered intramuscularly four days after the IUI for
luteal support. No supplemental progesterone was given.
Serum β-hCG was drawn 2 weeks after insemination.
Main outcome measure was the occurrence of multi-
ple pregnancy (≥3v e r s u s≥2 versus one gestational sac)
in resulting clinical pregnancies. Patients were classiﬁed
according to their principle infertility diagnosis: male factor,
tubal factor, endometriosis, ovulatory dysfunction, uterine
factor, or unexplained infertility. Ovulatory dysfunction was
further broken down into oligoovulation or anovulation due
to hypogonadotropic hypogonadism (WHO I), polycystic
ovary syndrome (WHO II), or diminished ovarian reserve
(WHO III). Male partners generally had at least 3 million
motile sperm in their processed specimens. Tubal patency
was conﬁrmed by laparoscopy or hysterosalpingogram. At
least one documented open fallopian tube was necessary.
Endometriosis was diagnosed at laparoscopy and classiﬁed
according to the American Society of Reproductive Medicine
(1996) classiﬁcation system. Assessment of ovulation was
based on history and midluteal serum progesterone. A mid-
luteal serum progesterone >5ng/mL was considered ovula-
tory. Patients with uterine factor had a history of a uterine
defect which was repaired by either operative hysteroscopy
Table 1: Patient- and cycle-speciﬁc parameters in live birth and no
live birth groups, mean (95% CI).
Live birth No live birth P
Female age (yrs) 33.2 (32.4–34.1) 35.7 (35.3–36.0) <0.001
Years of infertility 2.3 (1.9–2.8) 3.3 (3.0–3.6) 0.038
Basal FSH (IU/L) 8.3 (7.4–9.2) 8.4 (8.1–8.7) NS
Kruger (%) 11.0 (9.7–12.3) 10.7 (10.4–11.1) NS
Days of Gn. 9.4 (8.9–10.0) 9.1 (8.9–9.3) NS
Total Gn. (amp) 26.6 (23.4–29.7) 29.1 (27.9–30.3) NS
Max daily Gn.
(amp) 2.9 (2.6–3.2) 3.5 (3.2–3.8) NS
No. of follicles 2.4 (2.2–2.7) 2.6 (2.5–2.7) NS
TNMC (×106) 69.5 (54.9–84.1) 78.7 (72.2–85.2) NS
Max. EM thickness
(mm) 10.7 (10.2–11.3) 10.1 (9.9–10.2) NS
Peak E2 (pg/mL) 835.0
(737.0–933.0)
687.1
(654.0–720.1) 0.005
or open laparotomy prior to undergoing treatment. Unex-
plained infertility was diagnosed when there was no abnor-
mality found in the infertility evaluation of both partners.
Patient-speciﬁcandcycle-speciﬁcparameterswereexam-
ined. Patient-speciﬁc parameters included were female age,
duration of infertility, infertility diagnosis, highest basal FSH
level, previous use of clomiphene citrate, gonadotropins or
IVF, parity, ovulatory status, lowest Kruger’s morphology,
and use of husband versus donor sperm. Cycle-speciﬁc
parameters included were stimulation protocol, type of
gonadotropin used (recombinant, urinary, or combina-
tion), days of gonadotropin stimulation, total ampoules of
gonadotropin used, maximum daily dose of gonadotropins,
number of mature follicles, TNMC inseminated, maximum
endometrial thickness, and peak estradiol level.
Multiple logistic regression was used to evaluate predic-
tors of any multiple clinical pregnancy (2 or more gestational
sacs) or multiple high-order clinical pregnancy (3 or more
sacs). Sigma Stat (Version 2.0, 1997, SPSS Inc., Chicago,
IL, USA) was used for calculations. P value < 0.05 was
considered statistically signiﬁcant.
3. Results
428 women aged 18–46 underwent 861 gonadotropin-IUI
cycles, resulting in 95 live births (11.0% per cycle). The
clinical pregnancy rate was 13.8% per cycle (119/861).
Patient- and cycle-speciﬁc parameters associated with the
occurrence of live birth pregnancy were examined (Table 1).
We found that younger age, fewer years of infertility and
higher peak estradiol levels all predicted success, but that
no other factors were signiﬁcantly diﬀerent between the two
groups. Of the 95 pregnancies which ultimately resulted
in a livebirth (Table 2), at the end of the ﬁrst trimester 4
were quadruplets (4.2%), 7 were triplets (7.4%), 17 were
twins (17.9%), and 67 were singleton (70.5%). Of the high-
order multiple pregnancies (n = 11 or 11.6%), 8 underwent
elective fetal reduction (7 to twins and 1 to a singleton), andISRN Obstetrics and Gynecology 3
Table 2: Obstetrical outcome in live birth pregnancies by plurality.
Plurality n Obstetrical
management Birth outcomes
Quads 4
1 carried
3e l e c t i v ef e t a l
reduction to twins
A l ll o s ta t2 0w k s
all live births
Triplets 7
2 carried
5e l e c t i v ef e t a l
reduction (4 to twins,
1 to singleton)
1 delivered viable
triplets,
1 delivered triplets, 2
survived
4 delivered twins,
1 delivered singleton
Twins 17 17 carried
15 delivered viable
twins
2 spontaneously
reduced to singleton
Singleton 67 All carried All singleton
alldelivered viablechildren. Threeattempted tocarry:twoas
triplets (both women delivered viable triplets, but one child
died within 24 hours) and one as quadruplets (delivered 4
living children at 22 weeks but none survived). Thus, in our
small series, neonatal outcomes in those women who did not
undergo elective fetal reduction were not good.
All cycle and patient parameters in our database were
investigated as predictors of multiple clinical pregnancy by
looking at cycles which resulted in 1 gestational sac versus
those which resulted in ≥2o r≥3 gestational sacs. None of
the patient- or cycle-speciﬁc parameters examined (includ-
ing age and number of mature follicles) were signiﬁcant
predictors of the occurrence of any (≥2) or high-order (≥3)
multiple pregnancy (P>0.05).
For illustrative purposes, we present our data for some
factors which seemed likely (based upon previous studies)
to be useful predictors of multiple pregnancy. We hypoth-
esized that perhaps we might ﬁnd a useful cutoﬀ for cycle
cancellation to limit the occurrence of high-order multiple
pregnancy (3 or more sacs). It has been suggested that one
may cancel or convert to IVF those gonadotropin-IUI cycles
which seem to be at elevated risk and therefore prevent or at
least limit the occurrence of high-order multiple pregnancy.
Table 3 demonstratestherelationshipbetweenseveralfactors
which have [10] been proposed to limit the occurrence of
high-ordermultiplepregnancyandthedevelopmentofhigh-
order clinical pregnancy (≥3sacs) in our series. [Since single
sac clinical pregnancies are more likely than multiple sac
gestations to undergo spontaneous miscarriage, the high-
order multiple pregnancy rate per clinical pregnancy (9.2%)
is lower (11/119 clinical pregnancies contained 3 or more
sacs) as compared to the high-order multiple pregnancy rate
(11.5%) expressed as a percentage of ongoing or live birth
pregnancies(11/95ongoingpregnancieshad3ormoresacs).
We can evaluate the utility of some of these criteria
for cycle cancellation in our couples. For example, in our
series, 102/861 or 11.8% of cycles developed ≥5m a t u r e
follicles. Theoretically, if all of these cycles had all been
cancelled or converted into IVF due to excessive ovarian
response, 8 clinical pregnancies would have been prevented;
3 of which included ≥3sacs. The remaining 759 treatment
cycles in which ≤4 mature developed would have produced
111 clinical pregnancies, of which 8 (7.2%) would have
included ≥3sacs. Cancellation of those 102 cycles (nearly
12% of cycles) would have only slightly lowered (9.2 to
7.2%) the clinical high-order multiple pregnancy rate, which
would remain at 7.2%. Unfortunately, this risk of high-order
multiple pregnancy remains unacceptably high.
Insteadoffolliclenumber,wecantryusingpeakestradiol
level In our series, 133/861 or 15.4% of cycles developed
a peak estradiol level ≥1200pg/mL. Theoretically, if all of
these cycles had all been cancelled or converted into IVF
due to excessive ovarian response, 25 clinical pregnancies
wouldhavebeenprevented:4ofwhichincluded ≥3sacs.The
remaining 728 treatment cycles in which the peak estradiol
level was below 1200pg/mL would have resulted in 94
clinical pregnancies, of which 7 (7.4%) would still have
included ≥3sacs. Unfortunately, this risk of high-order
multiple pregnancy remains unacceptably high. Review of
Table 3 clearly demonstrates that no reasonable criteria
can be found which will reduce the occurrence of high-
order multiple pregnancy to acceptable levels and that these
extremely complicated pregnancies remain an unavoidable
side eﬀect of gonadotropin-IUI treatment.
4. Discussion
Our clinical pregnancy (13.8%) and live birth (11.0%) rates
are consistent with published data from other trials [2, 12–
15]. Although many trials have looked at clinical pregnancy
rates after gonadotropin-IUI treatments, few studies have
reported live birth rates—even though live birth is the
primary outcome of interest and therefore the most relevant
information for patient counseling.
The risk of high-order multiple pregnancy in our series
(11/95 or 11.6% of ongoing pregnancies were triplets or
quadruplets) was notable. Previous investigators [2, 7]
documentsimilarrisks,rangingfrom7to10%.Thedramatic
increase in obstetrical and neonatal risks associates with the
presence of high-order multiple pregnancies is well known
and necessitates careful patient counseling before embarking
upon gonadotropin-IUI therapy.
We found that the occurrence of multiple pregnancy
could not be predicted by any of the factors examined. In our
series, the number of follicles measured was not helpful in
predictingmultiplepregnancy.Severalpreviousinvestigators
have found that the number of follicles predicted multiple
pregnancy, although the critical size for the follicles in these
studies varied from 12 to 15mm. [6, 7, 17]. Dickey et al.
[7] reported on over 3600IUI cycles and noted a rate of 3
or more gestational sacs of 7.2%. They noted that diﬀerent
factors were critical in predicting the occurrence of high-
order multiple pregnancy at diﬀerent ages: under age 35,
the number of follicles ≥15mm was the best predictor of
high-order multiple pregnancy (and serum estradiol was
not useful), while in women aged 35–42, serum estradiol
level over 1,000pg/mL was the most useful predictor (and
number of follicles was not helpful). Our results conﬁrm4 ISRN Obstetrics and Gynecology
Table 3: Cancellation criteria to prevent high-order multiple pregnancy (≥3sacs) during gonadotropin-IUI cycles.
Clinical pregnancy
n = 119
Cycles
n = 861
≥2s a c s
n = 30
≥2sacs per clinical
pregnancy (%)
≥3sacs
n = 11
≥3sacs per clinical
pregnancy (%)
No. of mature follicles
1-2 68 490 15 15/68 (22.0%) 4 4/68 (5.8%)
3 23 173 3 3/23 (13.0%) 2 2/23 (8.6%)
4 20 96 6 6/20 (30.0%) 2 2/20 (10.0%)
≥5 8 102 6 6/8 (75.0%) 3 3/8 (37.5%)
Peak E2 (pg/mL)
≤800 62 558 11 11/62 (17.7%) 4 4/62 (6.4%)
801–1000 15 101 5 5/15 (33.3%) 2 2/15 (13.3%)
1001–1200 17 69 4 4/17 (23.5%) 1 1/17 (5.8%)
1201–1500 13 75 3 3/13 (23.0%) 3 3/13 (23.0%)
≥1500 12 58 7 7/12 (58.3%) 1 1/12 (8.3%)
Age
≤34 63 338 18 18/63 (28.6%) 8 8/63 (12.7%)
35–37 33 240 8 8/33 (24.2%) 2 2/33 (6.0%)
38–40 16 156 3 3/16 (18.7%) 0 0/20 (0%)
41-42 4 78 1 1/4 (25.0%) 1 1/4 (25.0%)
≥43 3 49 0 0/3 (0%) 0 0/3 (0%)
Max. daily
gonadotropin dose
≥5 18 194 2 2/18 (11.1%) 0 0/18 (0%)
4 17 129 3 3/17 (17.6%) 2 2/17 (11.7%)
3 32 186 7 7/32 (21.8%) 4 4/32 (12.5%
≤2.5 52 352 18 18/52 (34.6%) 5 5/52 (9.6%)
and extend those of Gleicher et al. [16], who noted that
peak serum estradiol level and/or number of preovulatory
follicles were not useful in predicting/preventing high-order
multiple pregnancy after gonadotropin-IUI. They suggested
that there is “... an unacceptably high incidence of high-
order multiple pregnancies after the induction of ovulation
with gonadotropins.” And also that “...better criteria cannot
easily be developed without negatively aﬀecting overall
pregnancy rates.” Unlike these authors, our study looked at
many other parameters beside estradiol and follicle number,
yet we were still unable to determine safe settings for cycle
cancellation which would prevent an unacceptable level of
high-order multiple pregnancies after this treatment.
Dickey published an updated analysis in 2009 [10],
including references from 130 articles, and developed several
conclusions. Risk factors for high-order multiple pregnancy
included ≥7 preovulatory follicles (≥10–12mm), E2 >
1,000pg/mL, early cycles of treatment, age < 32, low BMI,
and use of donor sperm. Unfortunately, cancellation of any
treatment cycle in which any one of these many criteria
occur would lead to very few completed cycles and would
becounterproductivetotherapeuticrelationship.Theauthor
did not provide speciﬁcs as to what combinations of these
risk factorscouldbeused toestablishreasonablecancellation
criteria. Based upon our analysis, we could determine no
clearcriteriawhichmaybeusedtoavoidhigh-ordermultiple
pregnancy which will not lead to the cancellation of an
unacceptably high % of treatment cycles.
Dickey [10] also claimed that age ≥ 38 was a low-
risk factor. Since our series included only 3 women ≥ 35
years with ≥ 3sacs, separate statistical analyses by female
age were not possible. But along with a lower rate of
multiple pregnancy, there was a much lower eﬃcacy in
terms of pregnancy success. It can be seen that high-order
multiple pregnancy rates declined along with overall clinical
pregnancy rates: ≤34 years 18.6% clinical pregnancies per
IUI cycle and 12.7% ≥ 3sacs, at 35–37 years 13.7% clinical
pregnancies per IUI cycle and 6.0% ≥ 3sacs, and at ≥38
years 8.1% clinical pregnancies per IUI cycle and 4.3% ≥
3sacs. Even in the older age groups, the rate of high-order
clinical pregnancies remains notable at 4.3%. Thus even
in the “older” group with a reduced chance of pregnancy
success, the rate of high-order multiple pregnancy remained
more than double the IVF triplet rate.
5. Conclusion
Gonadotropin-IUI carries a signiﬁcant risk of high-order
multiple birth (11.6%) among resulting viable pregnancies.
Cancellation of cycles in which elevated estradiol levels
(>1200pg/mL) or an excessive number of follicles (≥5)
develop would not reduce this risk to acceptable levels.ISRN Obstetrics and Gynecology 5
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